More than 10,000 patients Licensed US practitioners 100% Online

Semaglutide is the active ingredient in Wegovy®, Ozempic® and Rybelsus®, all made by Novo Nordisk. There is no generic semaglutide in the United States, so nothing competes the price down.

This page gives an approximate figure for each route as of September 2026: brand pricing, manufacturer self-pay, insurance pricing, the oral tablet, and telehealth pricing including our own. It also shows where the costs hide, because the headline number is almost never what you end up paying.

This question gets answered wrong constantly, so here is the precise position. There are two different oral semaglutide products and they are not interchangeable.

Rybelsus is oral semaglutide in 3mg, 7mg and 14mg tablets, approved for type 2 diabetes and available for years. Its list price was roughly $998 per month as of September 2026. Rybelsus is not approved for weight management.

Oral semaglutide 25mg is the higher-dose daily tablet developed for chronic weight management, which is what people usually mean by the Wegovy pill. Self-pay pricing has run substantially below the injection, in the region of $149 to $199 per month as of September 2026. That figure has moved more than any other number on this page, so take it as an order of magnitude and get the current price from NovoCare Pharmacy rather than from any article, including this one.

It is daily, not weekly. Oral semaglutide must be taken on an empty stomach, with no more than about 4 ounces of plain water, at least 30 minutes before eating, drinking anything else, or taking other oral medication. Absorption depends on that routine, so adherence matters more than with a weekly injection.

The side effect profile is broadly similar, since it is the same molecule: nausea, vomiting, diarrhea and constipation. And cost per month is not the only comparison. If the daily fasting routine does not fit your life, a cheaper product you take inconsistently is not cheaper.

Compiled from publicly listed pricing and approximate as of September 2026. Check each provider's own page before you rely on a number, because prices in this category move monthly. Society is in the table on the same terms as everyone else, and where a competitor is cheaper the table says so. Every figure here, ours included, is a published starting price.

Our brand Wegovy plans start at $1,695 per month, which is higher than NovoCare Pharmacy's self-pay price of around $499. We are not going to bury that.

If you want brand Wegovy at the lowest possible cost, can get a prescription, and are comfortable managing your own titration and side effects, the manufacturer's direct channel is cheaper than us and you should use it.

What a Society plan covers is a personalized treatment plan, your medication, labs, tailored compounded medication where a clinician determines it is appropriate, expedited shipping and continuous clinical assistance. Delivery is free and discreet, in 1 to 2 days. That is a bundled clinical service, not a pharmacy transaction, so the honest comparison is against a pharmacy price plus a separate office visit. Whether the bundle is worth the difference is a judgment only you can make, and we would rather you make it with the real numbers in front of you.

On the compounded side, our plans start at $149 per month, which is at the low end of the market. That is a starting price, not a flat rate, so the figure you should compare is the one you are quoted for the plan a clinician puts you on. Membership-only providers look cheaper at entry because medication is billed separately. Add the medication and compare twelve-month totals.

A compounded preparation is made by a pharmacy for one named patient, directed by that patient's prescriber. It is not a generic, not a discount version of a brand, and not a product you select. It exists where a clinician documents a clinical need the commercially available product does not meet, such as a documented allergy to an excipient in the approved product or a strength that is not commercially available.

The rules narrowed sharply in 2025. Since mid-2025, compounding a product that is essentially a copy of a commercially available drug has not been permitted for 503A pharmacies or 503B outsourcing facilities. On 30 April 2026, FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list. If finalized, the outsourcing-facility route closes permanently for these molecules, leaving only the narrow patient-specific 503A route.

Society's compounded semaglutide plans start at $149 per month, available only where a Society clinician determines that a commercially available product does not meet your clinical needs. Compounded medications are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy or quality. A compounded preparation is not a generic and is not the same product as Wegovy or Ozempic.

Six questions before you believe any low number, ours included. Is medication included, or is this a membership? A fee for prescriber access is not a medication price. Is that a starting price or the whole price? Almost every telehealth price you will see published, Society's included, is a starting price. Is it a first-month rate? Ask what months two and six cost. Does it require annual prepay? Ask the refund policy before you pay, not after. Are labs, consultations, dose changes and shipping billed separately? Four small charges are not small. What are the refund terms? Cancellation and refund are different questions.

Confirm your formulary status before assuming you are not covered. Ask specifically whether Wegovy is on formulary and what the prior authorization criteria are.

If you have established cardiovascular disease, ask about the cardiovascular indication. Some plans that exclude weight management medication will cover Wegovy under that separate indication. Only your plan can confirm.

If your plan excludes it, price NovoCare Pharmacy first. For brand semaglutide this is usually the lowest genuine cost.

If you have type 2 diabetes, ask about Ozempic coverage. Diabetes coverage is far more common than weight management coverage.

Use pre-tax dollars. GLP-1 medication prescribed for a diagnosed condition is generally HSA and FSA eligible, sometimes with a letter of medical necessity.

Ask whether a lower-cost medication is clinically appropriate. Metformin, from $99 per month at Society, is a different medication with different expected effects. That is a clinical conversation, not a price substitution.

See our full pricing page for everything we offer, or our guide to getting a GLP-1 without insurance if you have no coverage at all. If you are choosing between molecules, our tirzepatide cost page prices the other side.

Semaglutide plans start at $149 per month. The free 2-minute evaluation gives you your own figure, reviewed by a licensed US practitioner. You can pause, switch or cancel anytime, which stops future billing cycles, and the first two months of any treatment plan are non-refundable.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.